Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
123 Leser
Artikel bewerten:
(0)

ACell Launches New MatriStem Multilayer Wound Matrix Device

COLUMBIA, Md., Feb. 10, 2014 /PRNewswire/ --ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has launched the new MatriStem® Multilayer Wound Matrix device for deep, hard-to-heal, full-thickness wounds. The one-to-one (1:1) mesh design of MatriStem Multilayer Wound Matrix is built to accommodate moderate to heavy wound exudate and provides effective contouring functionality in wound application.

MatriStem products are medical devices that maintain and support a healing environment through constructive remodeling. Comprised of naturally-occurring urinary bladder matrix (UBM), MatriStem maintains an intact epithelial basement membrane which is hypothesized to facilitate the body's natural healing potential.

The MatriStem Multilayer Wound Matrix device is easy to prepare, apply and fixate and requires no special handling or storage requirements. MatriStem Multilayer Wound Matrix is appropriate for both acute and chronic wounds.

Jim DeFrancesco, Chief Executive Officer and Board Director, remarked, "ACell has developed MatriStem Multilayer Wound Matrix to address an unmet need in the area of acute and chronic wound care management. The launch of this new product provides a new option for physicians treating patients suffering from deep, hard-to-heal wounds."

MatriStem devices have received multiple 510(k) clearances from the FDA and are indicated for wound management including for pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds and trauma wounds, and the reinforcement of soft tissue where weakness exists in urological, gynecological and gastroenterological anatomy.

ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. Its patented MatriStem ECM medical devices maintain and support a healing environment through constructive remodeling and are available in particle and sheet forms for the treatment of acute wounds and various surgical procedures. For more information, visit www.acell.com.

About ACell, Inc.
ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products. Its medical devices are cleared for a variety of indications and are marketed under the brand name "MatriStem." A privately held company, ACell produces MatriStem at its full scale manufacturing facilities in Columbia, MD and Lafayette, IN, and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.

About MatriStem®
MatriStem products are porcine-derived extracellular matrix (ECM), essential structures that maintain and support a healing environment through constructive tissue remodeling. All MatriStem devices contain the basement membrane of porcine urinary bladder tissue, or urinary bladder matrix (UBM). UBM is a layer of tissue that is a critical component of constructive tissue remodeling. It provides MatriStem products with several distinguishable characteristics, including the ability to facilitate the body's own regenerative capabilities and help restore normal site-appropriate tissue while avoiding scar tissue formation; the ability to be used "off-the-shelf" and stored at room temperature, with an approximate two year shelf life; and superior ease-of-use characteristics. MatriStem products are indicated for use in a wide range of regenerative and tissue repair applications and come in a range of sizes and thicknesses. It is the only ECM of its kind available in micronized particulate form. It has been cleared for use for the reinforcement of soft tissue where weakness exists in urological, gynecological and gastroenterological anatomy, which is referred to as surgical soft tissue repair, and for the management of wounds, such as pressure ulcers, venous ulcers, diabetic ulcers, second-degree burns, surgical wounds and trauma wounds, which is referred to as complex wound management. Refer to IFU supplied with each device for indications, contraindications, and precautions. All MatriStem devices are made in the USA.

Contacts:

Cory West
Product Manager
(410) 715-1700

Kirsten Thomas (media)
The Ruth Group
(646) 536-7014
kthomas@theruthgroup.com

SOURCE ACell, Inc.

© 2014 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.